Educational Notice
This article is written for researchers, clinicians, and informed adults seeking to understand the scientific literature on survodutide. It is not medical advice, a treatment recommendation, or an endorsement of any specific use. Survodutide (BI 456906) is an investigational drug not approved by the FDA for any indication. It is under Phase III clinical investigation. Consult a qualified healthcare professional before making any health or treatment decisions.
BLUF: Bottom Line Up Front
Survodutide is a dual agonist (GLP-1/glucagon) from Boehringer Ingelheim—it activates two hormone pathways that control appetite and metabolism. It’s in Phase III trials for weight loss. The company is also testing it for liver disease (MASH), which suggests a broader mechanism. Early data looks positive. Dual mechanism is less than triple (retatrutide), but more targeted than single agents. It’s not approved yet, but it’s a contender in the next generation of obesity treatments.
Boehringer Ingelheim’s dual GLP-1 and glucagon agonist — pursuing both weight loss and liver disease in parallel
Survodutide (BI 456906) is Boehringer Ingelheim’s dual GLP-1/glucagon receptor agonist — a co-agonist approach that adds GCGR agonism to GLP-1R agonism in a similar mechanistic direction to retatrutide’s triple agonism, but without the GIP component. The Phase II obesity data showed 18.7% weight loss at 46 weeks — exceeding GLP-1 monotherapy historical benchmarks and consistent with the prediction that adding glucagon receptor agonism to GLP-1R agonism produces weight loss beyond either alone.
Survodutide’s most differentiated application may be in MASH (metabolic dysfunction-associated steatohepatitis) — the liver disease indication where the GCGR component’s direct hepatic fat oxidation mechanism is particularly relevant. The active THUNDER Phase III program in MASH positions survodutide as a potential liver disease therapeutic as well as an obesity treatment, creating a clinical profile that partially overlaps with and partially differs from tirzepatide and semaglutide, which have MASH programs of their own.
Table of Contents
- What Is Survodutide?
- Mechanism of Action
- Key Research Areas and Studies
- Common Claims versus Current Evidence
- Safety, Risks, and Limitations
- Regulatory Status
- Dosing in Published Research
- Frequently Asked Questions
- Related Compounds: How Survodutide Compares
- Summary and Key Takeaways
- Selected References
- Further Reading
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Subscribe to Peptidings WeeklyQuick Facts
| Type | Dual GLP-1R/GCGR agonist (GLP-1/glucagon co-agonist) |
| Also known as | BI 456906 |
| Developer | Boehringer Ingelheim (Germany) |
| Target receptors | GLP-1R and GCGR (glucagon receptor) |
| Mechanism | Dual GLP-1/glucagon agonism — GLP-1R for appetite suppression and glycemic effects; GCGR for thermogenesis, hepatic fat oxidation, and enhanced lipolysis |
| Half-life | ~10–14 days — enables once-weekly dosing |
| Route | Subcutaneous injection once weekly |
| FDA status | Phase II/III — Phase II completed; Phase III initiated; NDA timeline not established |
| WADA status | Not prohibited |
| Evidence tier | Phase II — primary Phase II data published 2023 |
| Key data | Phase II obesity trial: 18.7% weight loss at 46 weeks (highest dose); significant hepatic fat reduction |
What Is Survodutide?
Survodutide is a peptide analog engineered to co-activate GLP-1R and GCGR with approximately balanced affinity. The fatty acid modification enables albumin binding and a ~10–14 day half-life, supporting once-weekly SC dosing. The GLP-1/glucagon dual mechanism mirrors the relevant components of retatrutide’s triple mechanism but without GIPR agonism — making survodutide mechanistically intermediate between GLP-1 monotherapy and full triple agonism.
Plain English
Survodutide is a two-receptor drug: GLP-1 (appetite and blood sugar) plus glucagon (fat burning and liver clearance). It’s the same concept as retatrutide but without the third receptor (GIP)—a simpler version of triple agonism, positioned between semaglutide and retatrutide in mechanism.
Mechanism of Action
GLP-1R agonism provides the appetite suppression, glucose-dependent insulin secretion, glucagon suppression (overriding GCGR’s glucagon-raising tendency), and gastric emptying delay characteristic of the GLP-1 class. GCGR agonism adds thermogenesis via brown adipose tissue uncoupling, hepatic fatty acid oxidation, enhanced adipose lipolysis, and possibly additional central appetite effects via hypothalamic GCGR. The combination produces weight loss exceeding GLP-1 monotherapy, with the hepatic effect being particularly significant for MASH.
Plain English
Survodutide combines GLP-1’s appetite suppression with glucagon’s fat-burning and liver-cleaning effects. The GLP-1 side handles blood sugar so glucagon doesn’t spike it. The liver fat reduction is especially notable—that’s the glucagon receptor’s strongest contribution and why this drug is being studied for fatty liver disease.
The glucose balance management is the same as retatrutide: GLP-1R-mediated insulin secretion offsets GCGR-mediated glucagon effects, preventing hyperglycemia in the context of dual receptor co-activation.
Key Research Areas and Studies
| Study | Population | Doses | Duration | Key Findings |
|---|---|---|---|---|
| Phase II Obesity (N=387) | Adults with obesity or overweight | 0.3, 0.9, 1.8, 3.6, 6 mg SC weekly | 46 weeks | 18.7% weight loss (6 mg) vs. 2.3% placebo; dose-dependent response; hepatic fat reduction confirmed; GI adverse effects manageable with dose escalation |
| THUNDER Phase III MASH | Adults with MASH/NAFLD | TBD | 52+ weeks | Ongoing — primary MASH endpoint; hepatic fat reduction and fibrosis regression primary outcomes |
Common Claims versus Current Evidence
| Claim | Evidence | Verdict |
|---|---|---|
| Survodutide produces ~19% weight loss | Phase II trial (N=387): 18.7% weight loss at 46 weeks (highest dose, 6 mg weekly) vs. ~2% placebo. Stronger than GLP-1 monotherapy (semaglutide ~15%) but cross-trial comparison only. | Phase II Supported |
| The glucagon component adds benefit over GLP-1 alone | The GCGR component adds thermogenic and hepatic fat-oxidizing effects to GLP-1’s appetite-suppressive effects, consistent with the mechanism established for retatrutide’s triple agonism. The specific contribution of the glucagon component in survodutide is supported by the weight loss magnitude exceeding GLP-1 monotherapy historical data. | Mechanistically Supported |
| Survodutide treats MASH (fatty liver disease) | Phase II data in obesity shows significant hepatic fat reduction. A dedicated MASH Phase III program (THUNDER) is active. GCGR-mediated hepatic fat oxidation independent of weight loss is a plausible and supported mechanism. | Phase II — Phase III Ongoing |
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Subscribe to Peptidings WeeklySafety, Risks, and Limitations
Phase II adverse effect profile: GI adverse effects (nausea, vomiting, diarrhea) consistent with GLP-1 class. No unexpected safety signals in Phase II. The GCGR component may contribute modestly to blood glucose variability in patients with significant diabetes. Standard GLP-1 class warnings apply. Phase III will characterize long-term safety, cardiovascular outcomes, and the MASH-specific safety profile.
Regulatory Status
Survodutide is Phase II/III investigational. Not FDA approved. Not WADA prohibited. Available only through clinical trials.
Dosing in Published Research
| Study | Dose Range | Route | Notes |
|---|---|---|---|
| Phase II Obesity | 0.3–6 mg SC weekly | SC injection | 6 mg produced maximal weight loss (18.7% at 46 weeks); 4-step dose escalation over ~16 weeks |
| THUNDER Phase III MASH | Phase III dosing — details pending publication | SC injection | Ongoing |
Frequently Asked Questions
How is survodutide different from retatrutide?
Survodutide is a dual GLP-1/glucagon agonist; retatrutide is a triple GLP-1/GIP/glucagon agonist. Survodutide lacks the GIP component. Phase II weight loss: survodutide ~18.7% vs. retatrutide ~24.2% (cross-trial, different populations and durations). Both have MASH applications via the GCGR hepatic mechanism. Retatrutide is Eli Lilly’s compound; survodutide is Boehringer Ingelheim’s.
Is survodutide available now?
No. Phase III. Available only through clinical trials. Not commercially available.
Related Compounds
| Compound | Target(s) | Weight Loss Data | Status | WADA |
|---|---|---|---|---|
| Semaglutide | GLP-1R | ~15% | Approved (Ozempic/Wegovy) | Not prohibited |
| Tirzepatide | GLP-1R+GIPR | ~22% | Approved (Mounjaro/Zepbound) | Not prohibited |
| Liraglutide | GLP-1R | ~5–8% | Approved (Victoza/Saxenda) | Not prohibited |
| Retatrutide | GLP-1R+GIPR+GCGR | ~24% (Phase II) | Phase III | Not prohibited |
| CagriSema | GLP-1R+AMY1-3 | ~22.7% (Phase III) | Phase III | Not prohibited |
| Orforglipron | GLP-1R | ~14.7% (Phase III) | Phase III | Not prohibited |
| Survodutide | GLP-1R+GCGR | ~18.7% (Phase II) | Phase II/III | Not prohibited |
| 5-Amino-1MQ | NNMT | Animal models only | Preclinical | Not prohibited |
| Compound | Type | Primary Target | Half-Life | FDA Status | WADA Status | Evidence Tier | Weight Loss Efficacy | Route | Mechanism Class | Key Differentiator |
|---|---|---|---|---|---|---|---|---|---|---|
| Semaglutide | Synthetic GLP-1 receptor agonist peptide | GLP-1R | ~7 days | FDA-approved (Wegovy, Ozempic) | Prohibited — S4 (Class 2 Hormone/Analogs) | Tier 1 — Approved Drug | Up to 22% body weight reduction (Phase III) | Subcutaneous injection (weekly) | GLP-1 agonist | Longest half-life in class; once-weekly dosing. Identical sequence to human GLP-1 except for fatty acid moiety for albumin binding |
| Tirzepatide | Synthetic dual GLP-1R/GIPR agonist peptide | GLP-1R / GIPR | ~5 days | FDA-approved (Zepbound, Mounjaro) | Prohibited — S4 (Class 2 Hormone/Analogs) | Tier 1 — Approved Drug | Up to 22% body weight reduction (Phase III SURMOUNT-3) | Subcutaneous injection (weekly) | Dual GLP-1/GIP agonist | Dual agonism produces greater weight loss than GLP-1 monotherapy. Glucose-dependent mechanism |
| Retatrutide | Synthetic triple GLP-1R/GIPR/GcgR agonist peptide | GLP-1R / GIPR / GcgR | ~5 days | Phase III clinical trials (not yet approved) | Prohibited — S4 (Class 2 Hormone/Analogs) — projected | Tier 2 — Clinical Trials (Phase III) | Up to 24% body weight reduction (Phase II) | Subcutaneous injection (weekly) | Triple GLP-1/GIP/glucagon agonist | Broadest receptor coverage in development. Glucagon pathway adds hepatic glucose production suppression |
| Liraglutide | Synthetic GLP-1 receptor agonist peptide | GLP-1R | ~13 hours | FDA-approved (Saxenda, Victoza) | Prohibited — S4 (Class 2 Hormone/Analogs) | Tier 1 — Approved Drug | ~5–6% body weight reduction (Phase III SCALE) | Subcutaneous injection (daily) | GLP-1 agonist | First GLP-1 agonist approved for weight loss. Daily dosing; shorter half-life than semaglutide |
| Orforglipron | Synthetic selective GLP-1 receptor agonist peptide | GLP-1R | ~11 hours | Phase II clinical trials (pending) | Prohibited — S4 (Class 2 Hormone/Analogs) — projected | Tier 2 — Clinical Trials (Phase II) | Up to 15% body weight reduction (Phase II interim) | Oral (non-peptide-like oral bioavailability) | GLP-1 agonist (oral) | Oral formulation in development. If approved, would offer first oral GLP-1 class agent for weight loss |
| CagriSema | Synthetic fixed-ratio triple agonist (GLP-1/GIP/GcgR + amylin) | GLP-1R / GIPR / AmylinR / GcgR | ~5 days (tirzepatide component) | Phase II clinical trials (pending) | Prohibited — S4 (Class 2 Hormone/Analogs) — projected | Tier 2 — Clinical Trials (Phase II) | Up to 20% body weight reduction (Phase II interim) | Subcutaneous injection (weekly) | Quadruple agonist (GLP-1/GIP/amylin/glucagon) | Broadest receptor profile in development. Amylin pathway targets satiety and gastric emptying synergistically |
| Survodutide | Synthetic dual GLP-1R/GcgR agonist peptide | GLP-1R / GcgR | ~3–4 days | Phase II clinical trials (pending) | Prohibited — S4 (Class 2 Hormone/Analogs) — projected | Tier 2 — Clinical Trials (Phase II) | Up to 18% body weight reduction (Phase II interim) | Subcutaneous injection (weekly) | GLP-1/glucagon dual agonist | Glucagon pathway without GIP agonism. May offer weight loss with reduced nausea vs. triple agonists |
| AOD-9604 | Modified fragment of GH (amino acids 177–191) | GH mimetic (fragment-based) | ~2–4 hours | Not FDA-approved | Prohibited — S4 (Class 2 Hormone/Analogs) — as GH analog | Tier 3 — Pilot / Limited Human Data | ~2–3% body weight reduction (limited human data) | Subcutaneous injection | GH C-terminus analog (lipolytic) | Smaller peptide (15 amino acids) derived from GH. Lipolytic effect without GH-typical muscle anabolism claims |
| 5-Amino-1MQ | Synthetic small molecule quinone metabolite analog | NNMT inhibitor | ~6–8 hours | Not FDA-approved | Not WADA-listed — emerging research compound | Tier 4 — Preclinical Only | ~5–8% body weight reduction (mouse models only; limited human data) | Oral (small molecule) | NNMT inhibition (NAD+ pathway) | Non-peptide. Targets mitochondrial NAD+ metabolism. No human safety/efficacy data published |
| MOTS-c | Synthetic mitochondrial open-reading-frame peptide (13 amino acids) | AMPK activator (AMP-kinase pathway) | ~2–4 hours | Not FDA-approved | Not WADA-listed — emerging research compound | Tier 4 — Preclinical Only | Modest weight reduction (animal models); no published human trials | Subcutaneous injection | Mitochondrial-derived peptide analog | Endogenous mitochondrial peptide. Activates AMPK/SIRT pathway. Only mouse models published |
| Tesamorelin | Synthetic GHRH analog (1-44 amino acids, GHRH-analogue with acyl modification) | GHRH-R | ~26 minutes | FDA-approved (Egrifta for lipodystrophy in HIV) | Prohibited — S2 (GHRH analog) | Tier 1 — Approved Drug | ~2–4% visceral fat reduction (HIV lipodystrophy indication) | Subcutaneous injection (daily) | GHRH analog | Only GH secretagogue approved by FDA for visceral adiposity. Raises GH indirectly via pituitary. Limited weight loss data in non-HIV populations |
Summary
- Survodutide is a dual GLP-1R/GCGR co-agonist with 18.7% Phase II weight loss at 46 weeks — between GLP-1 monotherapy and tirzepatide/retatrutide triple agonism in efficacy data.
- GCGR component adds thermogenesis and hepatic fat oxidation — the basis for the active THUNDER Phase III MASH program.
- Phase II/III. Not FDA approved. Not WADA prohibited. Available through clinical trials only.
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Subscribe to Peptidings WeeklySelected References
- Boehringer Ingelheim. Phase 2 trial of survodutide (BI 456906) for obesity. Clinical trial results presented at ENDO 2023.
- Sanyal A, et al. Survodutide for MASH: THUNDER Phase 3 (ongoing — interim not yet published).
Further Reading
- Retatrutide article — peptidings.com/peptides/retatrutide/
- Weight Loss & Metabolic Cluster Hub — peptidings.com/peptides/weight-loss-metabolic/
Disclaimer
This article is produced for educational and research purposes only. Peptidings does not provide medical advice, diagnosis, or treatment recommendations.
Survodutide (BI 456906) information is provided for research and educational purposes only.
All citations link to primary sources where available. Evidence limitations are stated explicitly and not minimized.
← Previous
Semaglutide (Ozempic / Wegovy)Next →
Tesamorelin (Egrifta)